精密科学（EXAS）今日盘中股价大涨5.34%，引起市场广泛关注。截至发稿时，该股报价54.16美元/股，成交量达94.8584万股，换手率为0.50%，振幅6.50%。
此次股价上涨可能与加拿大皇家银行（RBC）最新的分析报告有关。RBC维持了对精密科学的"与大盘持平"评级，同时将目标价从52.00美元上调至54.00美元。这一目标价的调整显示出分析师对公司未来发展前景的积极看法，可能激发了投资者的信心。
精密科学是一家总部位于威斯康星州麦迪逊市的医疗诊断公司，主要提供癌症筛查和诊断测试产品。该公司的主打产品Cologuard是一种基于粪便的无创DNA测试，用于结肠癌和直肠癌的早期筛查。此外，精密科学还在开发用于分子残留疾病、结直肠癌筛查和多癌筛查的液体活检测试，显示出公司在癌症早期诊断领域的持续创新能力。近期财报显示，公司实现营业收入7.07亿美元，但净利润为-1.01亿美元，每股收益-0.54美元，反映出公司仍处于高速发展阶段。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.